Reuters logo
Morphosys moves closer to getting first antibody drug on market
October 1, 2016 / 4:15 PM / in a year

Morphosys moves closer to getting first antibody drug on market

FRANKFURT (Reuters) - German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.

Johnson & Johnson said earlier the experimental biotech drug proved more effective at clearing moderate to severe cases of the skin condition than a placebo or Abbvie’s Humira, the world’s top-selling prescription medicine.

A Morphosys spokesman said on Saturday that guselkumab could now become its first drug to market, depending on whether and when Johnson & Johnson makes an application.

Morphosys gets milestone payments during the development phase and would receive royalties from Johnson & Johnson once it goes on sale.

It has another drug in phase 3 study with Roche, for Alzheimer’s disease, and one in phase 2 - which in this case is likely to be the final phase - with Bayer, for asbestos-related lung cancer.

Reporting by Georgina Prodhan

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below